Nurix Therapeutics IncNRIX
Price$23.34Intrinsic value$10.6554% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $10.65median of 2 methodsbased on filings through 31 May 2026
Market Price $23.34Price as of 1 Oct 2026
Margin of Safety -54.4%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: -15.0% (near-term consensus, capped) · years 2–5: 61.1%/yr (balance of the path).41.8% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 652.9%Yr 744.6%Yr 836.4%Yr 928.2%Yr 1020.0%
61.1% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 11.8%
Volatility vs market (adjusted beta)1.52

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetNurix Therapeutics IncNRIXHealth Care
Valuation
P/E—
P/S72.0×
P/B7.2×
EV / Revenue70.1×
EV / EBITDA—
Profitability
Gross margin100.0%
Operating margin-1,466.7%
Net margin-928.4%
FCF margin-828.3%
Returns
ROE-84.8%
ROA-63.7%
ROIC—
Growth
Revenue growth (YoY)-32.6%
5-yr fwd EPS growth41.8%
Financial strength
Debt / Equity0.00×
Current ratio6.34×
Altman Z-Score7.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.